A Multiple-Dose Pharmacokinetics Study of Three Gefapixant (AF-219/MK-7264) Formulations

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

May 16, 2016

Primary Completion Date

June 15, 2016

Study Completion Date

June 21, 2016

Conditions
Healthy
Interventions
DRUG

Omeprazole

20 mg oral capsules administered once daily for 10 days

DRUG

Omeprazole

40 mg oral capsules administered twice daily for 10 days

DRUG

Gefapixant

Gefapixant oral tablets (15 mg administered as two 7.5 mg tablets) administered twice daily for 15 days

DRUG

Gefapixant

Gefapixant oral tablets (30 mg administered as four 7.5 mg tablets) administered twice daily for 15 days

Trial Locations (1)

85283

Celerion, Tempe

All Listed Sponsors
lead

Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

INDUSTRY

NCT02790840 - A Multiple-Dose Pharmacokinetics Study of Three Gefapixant (AF-219/MK-7264) Formulations | Biotech Hunter | Biotech Hunter